​

Enliven Therapeutics Stock (NASDAQ:ELVN)

ForecastOwnershipFinancialsChart
Enliven Therapeutics by TradingView

Previous Close

$16.51

52W Range

$13.30 - $30.03

50D Avg

$20.45

200D Avg

$23.28

Market Cap

$842.39M

Avg Vol (3M)

$267.10K

Beta

1.09

Div Yield

-

ELVN Company Profile

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

62

IPO Date

Mar 12, 2020

Website

ELVN Performance

ELVN Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-104.55M$-83.53M$-38.79M
Net Income$-89.02M$-71.58M$-37.75M
EBITDA$-104.55M$-81.93M$-38.58M
Basic EPS$-1.89$-2.01$-6.03
Diluted EPS$-1.89$-2.01$-6.03

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
GOSSGossamer Bio, Inc.
CMPXCompass Therapeutics, Inc.
KRONKronos Bio, Inc.
PMVPPMV Pharmaceuticals, Inc.
LYRALyra Therapeutics, Inc.
CELCCelcuity Inc.
GPCRStructure Therapeutics Inc.
REPLReplimune Group, Inc.
INBXInhibrx Biosciences, Inc.
CGEMCullinan Oncology, Inc.
AVTEAerovate Therapeutics, Inc.
MLTXMoonLake Immunotherapeutics
NVCTNuvectis Pharma, Inc.
IMRXImmuneering Corporation